AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2022

Mar 12, 2022

33148_dirs_2022-03-11_a5a08b03-e0e3-49d6-ab58-72280ac2f87a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2022-03-10

Reporting Person: Malik Fady Ibraham (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-10	Stock Option (Right to Buy)	$16.65	A	33199	Acquired	2032-03-10	Common Stock (33199)	Direct
2022-03-10	Stock Option (Right to Buy)	$16.65	A	8641	Acquired	2032-03-10	Common Stock (8641)	Direct

Footnotes

F1: This option represents a right to purchase a total of 33,199 shares of the Issuer's common stock, which will vest in equal monthly installments over a three-year period, such that all of the shares underlying this option will be fully vested on March 10, 2025.

F2: This option represents a right to purchase a total of 8,641 shares of the Issuer's common stock, which will fully vest on March 10, 2024.